Gerold Bepler began his tenure as president and chief executive officer of the Barbara Ann Karmanos Cancer Institute in Detroit in February 2010. Prior to coming to Karmanos, Dr. Bepler was Director of the Comprehensive Lung Cancer Research Center; Department Chair of Thoracic Oncology; and Program Leader of the Lung Cancer Program at the Moffitt Cancer Center in Tampa, FL. He also served as Professor of Medicine and Oncology at the University of South Florida. Prior to joining the Moffitt Cancer Center, Dr. Bepler was Director of the Lung Cancer Program at Roswell Park Cancer Institute in Buffalo, NY. He also held positions at Duke University Hospital and Durham VA Medical Center.

Dr. Bepler is a native of Germany. He received his medical and doctorate degrees from the Philipps University School of Medicine and Dentistry in Marburg, Germany. His postdoctoral fellowships were completed at the National Cancer Institute, Philipps University and at Duke University Medical Center.

David P. King is the executive chairman of LabCorp, retiring in 2019 as president and CEO after nearly two decades at the company, including almost 13 years as CEO. In his role as executive chairman, King continues to serve the company as a leader who operates with a strong emphasis on deeply understanding the healthcare industry, strategic planning, “playing the long game,” and staying ahead of rapidly evolving industry trends and challenges.

Prior to becoming CEO on Jan. 1, 2007, King served as LabCorp’s executive vice president and chief operating officer and as executive vice president of strategic planning and corporate development. King joined LabCorp as senior vice president, general counsel, and chief compliance officer in 2001 after serving for several years as the company’s principal outside legal counsel. Before joining LabCorp, he practiced law in Baltimore, first as an Assistant United States Attorney, then in private practice with Hogan & Hartson LLP (now Hogan Lovells).

King is the board chair of PATH, a nonprofit global health organization, and was appointed in 2017 to the advisory board for Duke University’s Robert J. Margolis, MD, Center for Health Policy. In addition, he serves on the boards of Elon University in Elon, North Carolina, and the American Clinical Laboratory Association (ACLA), where he served as chair from 2010 to 2014. King holds an AB degree, cum laude, from Princeton University and a JD degree, cum laude, from the University of Pennsylvania Law School.

Michael J. Campa is one of the scientific co-founders of Grid Therapeutics and has worked closely with Dr. Patz for 25 years. He developed or co-developed techniques for identifying potential biomarkers using MALDI-TOF MS, phage display, and immunological techniques. Much of the past 15 years has focused on the immunological response to cancer and the identification of antigens recognized by patient-expressed autoantibodies. It was this approach that led directly to the discovery of the autoantibody that has become Grid’s lead asset and the development of a new discovery platform for anti-cancer antibodies.

Before coming to Duke, Mike worked with Kwen-Jen Chang at Burroughs Wellcome Co. in Research Triangle Park, NC where he explored the roles of the Ras protein family in cancer. Dr. Campa received his PhD in biochemistry and molecular biology from the University of Florida in Gainesville, under the direction of Michael Kilberg.

Dr. Osarogiagbon is the Chief Scientist at Baptist Memorial Health Care Corporation, headquartered in Memphis, TN. He is Director of the Multidisciplinary Thoracic Oncology Program and the Thoracic Oncology Research Group at the Baptist Cancer Center and Principal Investigator of the Baptist Health System/Mid-South Minority-Underserved Consortium NCORP. He is a Research Professor at Vanderbilt University, and a member of the Vanderbilt Ingram Cancer Center.

Dr. Osarogiagbon’s research interests center around improving population-level outcomes of cancer care by improving care delivery systems and processes. He is a member of the NCI Cancer Prevention Steering Committee, the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee, the Fleischner Society and the Alpha Omega Alpha Honor Medical Society. He is board certified in the Internal Medicine subspecialties of Hematology and Medical Oncology, a Fellow of the American College of Physicians and member of American Society of Clinical Oncology and the American Society of Hematology.

Dr. Sarah Goldberg is an Associate Professor of Medicine in the division of Medical Oncology at the Yale School of Medicine and Yale Cancer Center.  She is the Division Chief for Thoracic Oncology, Research Director of the Center for Thoracic Cancers, and Associate Director of the Hematology/Oncology Fellowship Program at Yale. Her research interests include personalized medicine and immunotherapy for non-small cell lung cancer, with a focus on EGFR-mutant lung cancer and brain metastases.

Dr. Borghaei earned his degree at Philadelphia College of Osteopathic Medicine and completed a residency at Graduate Hospital in Philadelphia. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with lung cancer.

In addition to his clinical practice and participation in immunotherapy-based clinical trials, Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic.

Dr. Borghaei is the co-chair of the thoracic committee at Eastern Cooperative Oncology Group (ECOG) and the Chair of the LungMap trial (S1800/S1900). He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. He also is the recipient of the Robert Krigel Memorial Award for Teaching Excellence from Fox Chase Cancer Center. Dr. Borghaei is a long-standing member of ASCO, AACR, IASLC, SITC and ECOG thoracic committee.